advertisement

---

Fang YJ 15

Showing records 1 to 15 | Display all abstracts from Fang YJ

107594 Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Liu CH
Hepatology international 2023; 17: 291-302

---

108068 Splenic Arterial Pulsatility Index to Predict Hepatic Fibrosis in Hemodialysis Patients with Chronic Hepatitis C Virus Infection
Liu CH
Journal of clinical medicine 2023; 12:

---

107594 Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Peng CY
Hepatology international 2023; 17: 291-302

---

108068 Splenic Arterial Pulsatility Index to Predict Hepatic Fibrosis in Hemodialysis Patients with Chronic Hepatitis C Virus Infection
Fang YJ; Liu CJ
Journal of clinical medicine 2023; 12:

---

107594 Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Liu CJ; Chen CY
Hepatology international 2023; 17: 291-302

---

108068 Splenic Arterial Pulsatility Index to Predict Hepatic Fibrosis in Hemodialysis Patients with Chronic Hepatitis C Virus Infection
Su TH; Huang SC
Journal of clinical medicine 2023; 12:

---

107594 Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Lo CC
Hepatology international 2023; 17: 291-302

---

108068 Splenic Arterial Pulsatility Index to Predict Hepatic Fibrosis in Hemodialysis Patients with Chronic Hepatitis C Virus Infection
Tseng TC
Journal of clinical medicine 2023; 12:

---

107594 Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Tseng KC
Hepatology international 2023; 17: 291-302

---

108068 Splenic Arterial Pulsatility Index to Predict Hepatic Fibrosis in Hemodialysis Patients with Chronic Hepatitis C Virus Infection
Wu JH
Journal of clinical medicine 2023; 12:

---

107594 Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Su PY; Su PY; Kao WY
Hepatology international 2023; 17: 291-302

---

108068 Splenic Arterial Pulsatility Index to Predict Hepatic Fibrosis in Hemodialysis Patients with Chronic Hepatitis C Virus Infection
Chen PJ
Journal of clinical medicine 2023; 12:

---

107594 Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Tsai MC
Hepatology international 2023; 17: 291-302

---

108068 Splenic Arterial Pulsatility Index to Predict Hepatic Fibrosis in Hemodialysis Patients with Chronic Hepatitis C Virus Infection
Kao JH
Journal of clinical medicine 2023; 12:

---

107594 Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Tung HD; Cheng HT; Lee FJ; Huang CS; Huang KJ; Shih YL; Yang SS; Wu JH; Lai HC; Fang YJ; Chen PY; Hwang JJ; Tseng CW; Su WW; Chang CC; Lee PL; Chen JJ; Chang CY; Hsieh TY; Chang CH; Huang YJ; Kao JH
Hepatology international 2023; 17: 291-302

---